The Green Rush

Alternatively Speaking: Sebastian Brunemeier, Longevity Venture Capitalist

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we’re diving into a revolutionary concept in health span, longevity, and healthcare. Our hosts engage in a fascinating discussion with Sebastian Brunemeier, a true powerhouse in the longevity and regenerative medicine space. Sebastian is a biotech venture capitalist and company builder with a laser focus on extending human health span. As the co-founder and general partner of Healthspan Capital and the CEO and founder of ImmuneAgeBio, Sebastian is at the forefront of immune system rejuvenation research.  Over the past five years, he has co-founded four longevity biotech companies with a combined equity value exceeding $600 million. Sebastian’s background includes roles as co-founder and chief investment officer at Cambrian Biopharma, co-founder and COO of Samsara Therapeutics, and principal at Apollo Health Ventures, the world’s first and largest aging-focused venture capital fund managing $200 million in assets. Podcast Highlights: 1. Introduction to Sebastian Brunemeier (00:11): Overview of Sebastian’s background and his various roles in the longevity biotech space. 2. The Longevity Biotech Landscape (02:36): Discussion of Sebastian’s journey into longevity science and his mission to bring capital and talent into the field. 3. Healthspan Capital and Investment Strategy (27:48): Insights into Healthspan Capital’s approach to investing in longevity biotech companies. 4. The Global Demographic Aging Crisis (23:25): Exploration of the “silver tsunami” and how longevity science aims to address this global challenge. 5. Cutting-Edge Research in Longevity (39:54): Discussion of promising studies in the longevity space, including blood plasma research and stem cell therapies. 6. The Political and Social Movement of Longevity (45:00): Introduction to the concept of startup cities and the Prospera project as hubs for longevity research and development. 7. Personal Longevity Practices (53:35): Sebastian’s insights on personal health protocols and cautionary advice on experimental interventions. Social Media: * X: @sebastian_gero [https://x.com/sebastian_gero?lang=en] * LinkedIn: https://www.linkedin.com/in/sebastianlongbio/ [https://www.linkedin.com/in/sebastianlongbio/]  Other Links/Mentions/Resources: * LongevityList.com: https://longevitylist.com/ [https://longevitylist.com/]  * Stranded Technologies Podcast interview: https://www.strandedtechnologies.com/p/ep-15-sebastian-a-brunemeier-on-the-9b0 [https://www.strandedtechnologies.com/p/ep-15-sebastian-a-brunemeier-on-the-9b0]  * ImmuneAgeBio: https://immuneage.bio/ [https://immuneage.bio/]  * Healthspan Capital: https://www.healthspancapital.vc/ [https://www.healthspancapital.vc/]  Show Credits: This episode was hosted by Anne Donohoe and Phil Carlson of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com [http://www.kcsa.com/] or emailing AltSpeaking@kcsa.com [AltSpeaking@kcsa.com]. You can also connect with us via our social channels: X: @KCSAPodcastLabs [https://twitter.com/kcsapodcastlabs]Instagram: @KCSAPodcastLabs [https://www.instagram.com/kcsapodcastlabs/]LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/ [https://www.linkedin.com/company/kcsapodcastlabs/]

Alternatively Speaking: Petr Sramek, Investing in Longevity Tech

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we’re diving into a revolutionary concept in health span, longevity, and healthcare. Hosts Phil Carlson and Anne Donohoe dive into the world of longevity technology with guest Petr Sramek, a visionary in the field of longevity tech. Petr is the co-founder, chairman, and managing general partner of the Longevitytech.fund, bringing over 33 years of experience as a serial tech entrepreneur to the table. His impressive resume includes being a former entrepreneur-in-residence at Singularity University and co-founder of theLongevityForum.eu. Currently serving on the boards of several cutting-edge companies in the longevity sector, including Animal Biosciences in the U.S. and Age Curve in the U.K., Petr is dedicated to building the scientific, financial, and business infrastructure needed to accelerate the adoption of technologies that improve our health span. Podcast Highlights: 1. Introduction of Petr Sramek (00:11): Overview of Petr’s background as co-founder and chairman of the Longevity Tech Fund and his experience in technology entrepreneurship. 2. Concept of “Healthy Longevity” (02:48): Explanation of the focus on expanding the healthy and active part of life rather than just extending the overall lifespan. 3. Longevity Tech Fund Investment Strategy (17:35): Discussion of investment ticket sizes ranging from $100,000 to $600,000 and the fund’s approach to selecting companies. 4. Longevity vs Traditional Biotech (29:34): Differentiation between longevity and traditional biotech investments, highlighting that aging is not classified as a disease. 5. CRISPR and Gene Therapy in Longevity (37:33): Examination of CRISPR’s current limitations in longevity applications and the potential of gene therapy as a more relevant near-term approach. 6. Advice for Investors and Companies (42:54): Guidance for retail investors interested in the longevity space and information on how companies can pitch to the Longevity Tech Fund. 7. Personal Longevity Practices (47:30): Petr’s sharing of his own experiences with longevity interventions, including his epigenetic age results showing a 16-year difference from his chronological age. Social Media: * Petr’s LinkedIn: https://www.linkedin.com/in/petrsramek/ [https://www.linkedin.com/in/petrsramek/]  * X: https://x.com/petrsramekbench [https://x.com/petrsramekbench]  Other Links/Mentions/Resources: * Longevitytech.fund: https://www.longevitytech.fund/en/home [https://www.longevitytech.fund/en/home]  * Longevity Forum EU: https://www.longevityforum.eu/en/home [https://www.longevityforum.eu/en/home]  * HealthyLongevity.clinic: https://www.healthylongevity.clinic/ [https://www.healthylongevity.clinic/]  * Singularity University: https://www.su.org/ [https://www.su.org/]  * AgeCurve: https://agecurve.co.uk/ [https://agecurve.co.uk/]  * Animal Bioscience: https://animalbioscience.com/about-us/ [https://animalbioscience.com/about-us/]  Show Credits: This episode was hosted by Phil Carlson and Anne Donohoe of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com [http://www.kcsa.com/] or emailing AltSpeaking@kcsa.com [AltSpeaking@kcsa.com]. You can also connect with us via our social channels: * X: @KCSAPodcastLabs [https://twitter.com/kcsapodcastlabs] * Instagram: @KCSAPodcastLabs [https://www.instagram.com/kcsapodcastlabs/] * LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/ [https://www.linkedin.com/company/kcsapodcastlabs/]

Alternatively Speaking: Lou Reese, Next-Gen Vaccines

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we’re diving into a revolutionary concept in health span, longevity, and healthcare. We sat down with Lou Reese, co-founder and Vice Chairman of Vaxxinity, a purpose-driven biotechnology company pioneering a new class of medicines aimed at disrupting existing treatments for chronic diseases. Founded in 2014 alongside his wife and CEO, Mei Mei Hu, Vaxxinity is at the forefront of developing “next generation” vaccines for chronic conditions such as Alzheimer’s, Parkinson’s, heart disease, and migraine. Lou Reese also serves on the Executive Committee of United Biomedical, Inc. (UBI), a multinational biopharmaceutical organization focused on developing diagnostics and immunotherapeutics for global health improvement. Lou was a director at ShenLian Biotech, one of the largest animal health companies in China, and co-founded an investment firm with ventures spanning real estate, energy, hospitality, and life sciences. Podcast Highlights: 1. Introduction & Lou Reese’s Background (3:00): Lou’s journey and his mission to eliminate global suffering. 2. Synthetic Peptide Technology (10:15): Discussion of Vaxxinity’s innovative approach to vaccine development. 3. Active Immunotherapy Medicines (18:30): Vaxxinity’s work on developing active immunotherapy medicines. 4. Parkinson’s Disease Breakthrough (23:45): Promising results from Vaxxinity’s Parkinson’s trials. 5. Company Restructuring (32:00): Vaxxinity’s decision to delist and deregister, and plans for becoming a B Corp. 6. Army of Compassion (41:30): Global prevention trial for Alzheimer’s and partnership with former Governor David Beasley. 7. Future of Healthcare (48:45): Lou’s vision for affecting billions of lives and revolutionizing healthcare spending. Social Media: * Lou Reese’s LinkedIn: https://www.linkedin.com/in/lou-reese-6b54504/ [https://www.linkedin.com/in/lou-reese-6b54504/]  * X: https://x.com/notloureese [https://x.com/notloureese]  Other Links/Mentions/Resources: * Vaxxinity’s official website: https://www.vaxxinity.com/ [https://www.vaxxinity.com/]  * World Food Programme: https://www.wfp.org/ [https://www.wfp.org/]  * Mayo Clinic: https://www.mayoclinic.org/ [https://www.mayoclinic.org/]  * UT Health: https://www.uthscsa.edu/ [https://www.uthscsa.edu/]  * Amprion: https://www.amprionme.com/ [https://www.amprionme.com/]  * United Therapeutics: https://www.unither.com/ [https://www.unither.com/]  Show Credits: This episode was hosted by Lewis Goldberg of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com [http://www.kcsa.com/] or emailing AltSpeaking@kcsa.com [AltSpeaking@kcsa.com]. You can also connect with us via our social channels: X: @KCSAPodcastLabs [https://twitter.com/kcsapodcastlabs]Instagram: @KCSAPodcastLabs [https://www.instagram.com/kcsapodcastlabs/]LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/ [https://www.linkedin.com/company/kcsapodcastlabs/]

Alternatively Speaking: Dr. Bob Hariri, Evolution of Cellular Medicine

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we’re diving into a revolutionary concept in health span, longevity, and healthcare. We sat down with Dr. Bob Harari, a renowned biomedical scientist, surgeon, and entrepreneur. He is the Founder, Chairman, and CEO of Celularity, a biotechnology company leading the next evolution in cellular medicine. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration.  Dr. Hariri is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 150 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Podcast Highlights: * Introduction & Dr. Bob Harari’s Research (1:00): Dr. Harari’s background and journey to longevity science. * Placental Stem Cells (04:30): Advantages of using placental-derived stem cells and their ethical considerations. * Universal Donor Tissue (10:05): Concept of the placenta as a universal donor tissue is explored, highlighting its potential in cellular therapies. * Genetic Modification (12:40): Process of genetic modification in stem cells and their natural intelligence. * Chimerism (20:35): The potential therapeutic benefits of chimerism in cellular medicine are discussed. * Adult Stem Cell Banking (24:18): Cellularity’s adult stem cell banking program and its value for future treatments. * Future of Stem Cell Medicine (36:40): A vision of stem cell medicine in 10 years, including potential treatments for cancer, autoimmune diseases, and aging-related conditions. Social Media: * Dr. Bob Hariri’s Instagram: https://www.instagram.com/drbobhariri/?hl=en [https://www.instagram.com/drbobhariri/?hl=en]  * Dr. Bob Hariri’s LinkedIn: https://www.linkedin.com/in/bob-hariri-md-phd-3654b239/ [https://www.linkedin.com/in/bob-hariri-md-phd-3654b239/]  Other Links/Mentions/Resources: * Cellularity’s official website: https://www.cellularity.com/ [https://www.cellularity.com/]  * National Institutes of Health (NIH) information on stem cells: https://stemcells.nih.gov/ [https://stemcells.nih.gov/]  * FDA resources: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products [https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products]  * Nature article on chimerism: https://www.nature.com/articles/d41586-021-01001-2 [https://www.nature.com/articles/d41586-021-01001-2]  * The American Society for Gene and Cell Therapy’s patient education page: https://asgct.org/education [https://asgct.org/education]  Show Credits: This episode was hosted by Lewis Goldberg of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com [http://www.kcsa.com/] or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels: * X: @KCSAPodcastLabs [https://twitter.com/kcsapodcastlabs] * Instagram: @KCSAPodcastLabs [https://www.instagram.com/kcsapodcastlabs/] * LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/ [https://www.linkedin.com/company/kcsapodcastlabs/]

Alternatively Speaking: Dr. Moshe Szyf, Epigenetics Pioneer

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we’re diving into a revolutionary concept in health span, longevity, and healthcare. Our hosts sat down with Dr. Moshe Szyf, a pioneering figure in the field of epigenetics with a career spanning over three and a half decades. A founding figure in behavioral and psychiatric epigenetics, Dr. Szyf has authored over 300 influential papers that have significantly contributed to our understanding of how environmental factors and behaviors can influence gene expression without altering the DNA sequence itself.  Dr. Szyf serves as Chairman, CEO, and Chief Scientific Officer of HKG Epitherapeutics, focusing on developing epigenetic tools for clinical medicine, early disease detection, and personalized healthcare. He also currently holds the prestigious position of James McGill Professor of Pharmacology and Therapeutics at McGill University in Montreal, where he also holds the GlaxoSmithKline Chair in Pharmacology.  Podcast Highlights: * Introduction to Epigenetics (00:11 – 02:37): Dr. Moshe Szyf is introduced as a pioneer in epigenetics. The concept of epigenetics is explained as the “software” that programs DNA, influencing how genes function without changing the DNA sequence itself. * HKG Epitherapeutics and Epigenetic Testing (02:38 – 06:05): Discussion of Dr. Szyf’s company, HKG Epitherapeutics, which develops epigenetic tests for early disease detection, aging assessment, and health monitoring. * Epigenetics vs. Traditional Testing (06:06 – 09:44): Explanation of how epigenetic testing differs from traditional blood tests and genetic testing, offering insights into the dynamic changes happening at the DNA level. * Consumer Impact and Health Empowerment (09:45 – 14:42): Examples of how consumers have used epigenetic tests to gain insights into their biological age and health status, leading to lifestyle changes. * COVID-19’s Impact on Healthcare Autonomy (29:38 – 33:40): Discussion on how the pandemic has led to increased public interest in personal health management and a shift towards more patient autonomy in healthcare decisions. * Future of Precision Medicine (39:12 – 42:06): Dr. Szyf’s views on the role of epigenetics in precision medicine, particularly in guiding personalized drug treatments and lifestyle interventions. * Ethical Considerations and Balanced Approach to Longevity (34:55 – 39:11): Dr. Szyf’s perspective on extreme anti-aging approaches, emphasizing the importance of balance and quality of life over extreme life extension methods. * Future Developments in Epigenetics (43:25 – 45:37): Discussion of anticipated breakthroughs in epigenetic technology, including improved accuracy in testing and applications for early detection of various chronic diseases. Social Media: * LinkedIn https://www.linkedin.com/in/moshe-szyf-99ab283/?originalSubdomain=ca [https://www.linkedin.com/in/moshe-szyf-99ab283/?originalSubdomain=ca]  * @epimedtech https://twitter.com/epimedtech [https://twitter.com/epimedtech]  Other Links/Mentions/Resources: * EpiMedTechGlobal https://epimedtech.com/ [https://epimedtech.com/]  * Dr. Szyf’s Ted Talk https://www.ted.com/talks/moshe_szyf_how_early_life_experience_is_written_into_dna?subtitle=en [https://www.ted.com/talks/moshe_szyf_how_early_life_experience_is_written_into_dna?subtitle=en]  * CDC Resources for Epigenetics https://www.cdc.gov/genomics-and-health/about/epigenetic-impacts-on-health.html [https://www.cdc.gov/genomics-and-health/about/epigenetic-impacts-on-health.html]  Show Credits: This episode was hosted by Anne Donohoe and Phil Carlson of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com [http://www.kcsa.com/] or emailing greenrush@kcsa.com. You can also connect with us via our social channels: * X: @KCSAPodcastLabs [https://twitter.com/kcsapodcastlabs] * Instagram: @KCSAPodcastLabs [https://www.instagram.com/kcsapodcastlabs/] * LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/ [https://www.linkedin.com/company/kcsapodcastlabs/]